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1. Introduction 
For a long time, obesity has been known as a risk factor for cardiovascular disease, which is one 
of the main causes of death in developed countries. The prevalence of obesity (defined as 
having a body mass index [BMI] of  30 kg/m2 or more) is increasing in both developing and 
developed countries. A 5-kg/m2 increase in body mass index (BMI) increases the risk of cardiac 
complications by 29% [1]. This risk is due to the coexistence of other factors associated with 
obesity, such as hypertension, dyslipidemia, nonalcoholic fatty liver disease and abnormalities 
in glycemic metabolism. Resistances to insulin and lipid abnormalities are commonly found 
among obese patients with type 2 diabetes mellitus (T2DM) and are strongly related to an 
increase of cardiovascular risk.  Resistance to insulin and consequent compensatory 
hyperinsulinemia significantly increase the risk of death due to cardiovascular diseases [2–5]. 
To identify the patients with metabolic syndrome, insulin resistance, and greater 
cardiovascular risk, there are criteria, established by the Adult Treatment Panel III (NCEP 
ATP III), that include the presence of three of more of the following: central obesity 
(abdominal circumference above 102 cm in men and 88 cm in women), increased 
triglycerides (greater than or equal to 150 mg/dl) or use of a lipid-lowering agent, reduced 
HDL cholesterol (lower than 40 mg/dl among men and lower than 50mg/dl among women) 
or use of a lipid lowering agent, hypertension (systolic arterial pressure greater than or 
equal to 130 mmHg or diastolic pressure greater than or equal to 90mmHg) or use of an 
antihypertensive agent, andglucose levels greater than or equal to 100 mg/dl or use of an 
oral hypoglycemic agent and/or insulin [6]. 
Despite this, recent studies propose that the use of the TG/HDL (Triglicerides/High Density 
Lipoprotein) ratio may be a more practical way to estimate insulin resistance. It is believed 
that the greater the ratio, the greater the insulin resistance of the patient. This ratio provides 
an estimate of the sensitivity to insulin and is as accurate as the criteria for the metabolic 
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syndrome defined by the ATP III, the concentration of plasma insulin when fasting, or other 
estimates that measure the amount of glucose and the plasma concentration of insulin in 
order to evaluate its action [5, 7 -9]. Some studies suggest that the increase of the TG/HDL 
ratio may better predict the risk of cardiovascular diseases than do conventional risk factors 
such as hypertension, tobacco use, and physical activity [10]. 
To control the obesity and insulin resistance the initial steps are lifestyle changes aimed at 
controlling diet and increasing activity with the goal of reducing body weight, followed by 
the addition of orally active pharmacologic agents and insulin to the treatment regimen. 
However, dietary modification and pharmaceutical therapy offer limited potential for 
sustained weight loss, effective in fewer than 5% of cases [2]. In a meta-analysis of 
pharmacotherapy for obesity, the percentages of patients achieving 5% and 10% weight loss 
thresholds by using anti obesity drugs were 54% and 18%, respectively, but a lack of 
adherence to treatment limited the efficacy and effectiveness [11].  
Weight loss surgery, in contrast, has been shown to effect a more durable response . In 
addition, it can induce reversal of obesity-associated comorbidities [2,12].  
Of interest is the observation that obese patients with diabetes who undergo certain gastric 
bypass procedures demonstrate improvement in glycemia, often within days of surgery and 
before significant weight loss. The exact mechanism responsible for this dramatic effect of 
surgical procedures for obesity on diabetes improvement is not fully understood; however, 
the surgical rearrangement of the anatomy of the gastrointestinal (GI) tract changes the 
location where partially digested nutrients first contact the intestine, suggesting that 
correction of dysfunctional homeostatic mechanisms may contribute to the glycemic 
improvement. Whether it is a pure effect of weight reduction or bypass of the hormonally 
active foregut has a primary effect remains a controversy. Hypothesis includes weight 
reduction, decreased caloric intake, and bypass of the hormonally active foregut [12-14]. 
However, weight loss surgery is associated with complications such as anastomotic leak and 
ulcer presenting a mortality rate estimates range between 0.1 and 2.0% [2]. 
Endoscopic weight loss therapies may provide some of the benefits of weight loss surgery 
while being reversible, with a lower risk profile, and being available to patients who do not 
qualify for surgery or are poor candidates for surgery. Those endoscopic solutions for 
weight loss are also applicable as metabolic procedures to address comorbidities as type 2 
diabetes, dyslipidemia and nonalcoholic fatty liver disease. 
2. Physiopathology of metabolic improvement after metabolic surgery 
Several studies have shown a significant diabetes improvement in obese patients  who 
undergo certain gastric bypass procedures. The improvement of glycemia is observed, often 
within days of surgery and before significant weight loss. The  mechanism responsible for 
this improvement is not fully understood; however, the surgical rearrangement of the 
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anatomy of the gastrointestinal tract may contribute to the glycemic improvement. If the 
glicemic improvement is a pure effect of weight reduction or bypass of the hormonally 
active foregut has a primary effect remains a controversy. Hypothesis to explain those 
effects includes weight reduction, decreased caloric intake, and bypass of the hormonally 
active.foregut. [12-14] 
Two hypothesis have been proposed to explain the effect of duodenal jejunal bypass on type 
2 diabetes. The “hindgut hypothesis” holds that diabetes control results from the expedited 
delivery of nutrient chyme to the distal intestine, enhancing a physiologic signal that 
improves glucose metabolism. A potential candidate mediator of this effect is glucagon-like 
peptide 1 (GLP-1). This incretin hormone is secreted by L cells of the distal bowel in 
response to intestinal nutrients. It stimulates insulin secretion and exerts proliferative and 
antiapoptotic effects on pancreatic beta cells.16 If proven true, the hindgut hypothesis would 
spur further research on methods to enhance signaling by GLP-1 (or other distal gut 
peptides) to treat type 2 diabetes [14-16]. An alternative hypothesis is that the effect of 
selected bariatric operations on diabetes depends on exclusion of the duodenum and 
proximal jejunum from the transit of nutrients, possibly preventing secretion of a putative 
signal that promotes insulin resistance and type 2 diabetes (“foregut hypothesis”). Although 
no obvious candidate molecules can be identified with current knowledge, if proven true, 
this hypothesis might open new avenues in the search for the cause and cures of diabetes 
[14,17,18].  
Several reports supported that the duodeno jejunal exclusion (foregut hypothesis) owes to a 
direct effect of the bypass of the hormonally active foregut.  Rubino and Marescaux showed 
in their study in animal model that bypassing a short segment of proximal intestine  directly 
ameliorates type 2 diabetes, independently of effects on food intake, body weight, 
malabsorption, or nutrient delivery to the hindgut [14]. 
However,in previous studies, it was observed that a strict calorie restriction, as performed in 
the first weeks after bariatric surgery, could bring itself to a normalization of plasma glucose 
and insulin levels before body weight decrease [19,20]. 
Wei-Jei Lee in a study comparing the band (restrictive) with the gastric bypass (duodeno 
jejunal bypass), with a longer follow-up, showed that the gastric banding group had a 
similar improvement of insulin resistance to the bypass group while similar weight 
reduction was achieved. The gastric banding group had similar result at postoperative 6 
months compared to the gastric bypass group at the first postoperative month. Also, 3 
months to 1 year and 6 months to 2 years were compatible. Suggesting that  for a long-
term effect of resolution of insulin resistance, sustained weight reduction plays the key 
mechanism [12]. 
Improvement in the glycemic control,  insulin resistance and metabolic syndrome after 
bariatric surgery is regulated by a complex  mechanism and still there is no certainty 
whether it is a pure effect of calorie restriction and weight reduction or it is caused by the 
bypass of the hormonally active foregut . 
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3. Metabolic improvements with the intragastric baloon 
The intragastric baloon is a spherical silicone elastomer balloon that is resistant to 
degradation by gastric acid for approximately 6 months. It can be placed endoscopicallyand 
filled with 400 to 700 ml of saline and methylene blue dye, which changes the color of the 
urine in the event of balloon rupture.  
Balloon insertion and removal are performed under conscious sedation or general 
anesthesia. Before the insertion, an upper gastrointestinal endoscopy is performed to detect 
possible contraindications to the procedure.  The baloon placement device is inserted 
through the mouth into the stomach. Then the balloon is positioned in the fundus under 
endoscopic control, and inflated by injecting saline mixed with 10-ml methylene blue into 
the catheter. Finally, once the desired volume has been injected, the balloon is released by a 
short pull on the catheter. The baloon should be removed after a maximum of 6 months 
because beyond this period, the risk of spontaneous balloon deflation significantly increases. 
A meta-analysis by Imaz et al. [21] of 15 studies comprising 3698 patients estimated 14.7 kg 
weight loss, 32.1% excess weight loss (EWL), and 5.7 kg/m2 decrease in BMI after 6 months. 
In a review including 22 studies with a total of 4371 patients implanted with the intragastric 
baloon,  demonstrated a mean weight loss  of 17.8 Kg, with extremes of the means of 4.9–
28.5 kg and higher absolute values observed in higher BMI categories. [22]. 
A prospective study, evaluating the effect of the baloon on weight, insulin resistance, and 
liver steatosis in obese patients showed that 76% of the patients had a BMI decrease of 3.5 
Kg/m2 or more. The mean (SD) weight loss with respect to baseline values was 16.4 (8.2) kg 
with a corresponding mean (SD) BMI reduction of 6.4 (3.2) kg/m2. The absolute percentage 
of participants with glycemia levels of 100 mg/dL or higher decreased from 50% to 12%, 
those with triglyceridemia 150 mg/dL or higher from 58% to 19%, and those with abnormal 
ALT level from 38% to 7% [23]. 
Two studies (one randomized, one uncontrolled) totaling 143 patients have reported that, 
one year after BIB removal, patients had regained 41% and 28% (mean values, respectively) 
of the absolute weight loss observed at BIB removal [24,25]. Another study following 88 
patients for a median of 22 month after baloon withdrawal, observed that (50%) regained 
some weight, 34 (39%) maintained their weight, and the remaining 10 (11%) continued to 
lose weight [23]. 
It is also important to consider that 20–40% of patients fail to achieve a significant weight 
loss (often defined as ≥10% baseline weight or ≥25% excess weight). Such failures may be 
related to the request of early baloon removal by patients who present a digestive or 
psychological intolerance to the baloon, to the early vanishing of anticipated effects on 
hunger and early satiety, or to patient’s adaptation of food intake [23]. 
In conclusion, the BIB strategy may be an alternative to current management of obesity 
focused on lifestyle changes, drug therapy, and treating associated metabolic 
complications. 
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Although the baloon has not yet proved to be a convincing means of primary long term 
weight loss, it holds some promise for improving co-morbidities and quality of life in 
nonmorbidly obese patients or those who are unwilling to undergo bariatric surgery. New 
perspectives are also beginning to show its potential value in specific patient groups 
especially, for example, those preparing for surgery.  
4. Metabolic improvements with duodeno jejunal bypass liner 
A totally different concept, that of mimicking principles of bariatric surgery, has recently 
been applied in the development of the endoscopic duodenal-jejunal bypass liner. In 
addition to early satiety and delayed gastric emptying, the intraluminal sleeve aims at 
creating a duodenojejunal exclusion.  
The DJBL is a sterilized, single-use endoscopic device, which is minimally invasive and 
employed under radioscopic control. It is composed of a nitinol anchoring with tiny lateral 
barbs for fixation and an impermeable plastic conduit made of a fluorine polymer 62 cm in 
length, which impedes contact of the chyme with bile–pancreatic secretions prior to the 
proximal segments of the jejunum. FIGURE 1 
 
Figure 1. Impermeable plastic conduit and anchor system. 
Endoscopic implantation is performed under general anesthesia. The device is introduced 
over a guidewire that has been previously positioned in the duodenal bulb with endoscopic 
assistance. The plastic conduit is stretched to overlay the duodenum and the proximal 
region of the jejunum. After the correct positioning of the plastic conduit, the anchoring 
system is freed, setting the device in the duodenal bulb. The infusion of a contrast agent is 
performed to verify the correct positioning of the prosthesis and the absence of obstructions 
within the plastic conduit. FIGURE 2  
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Figure 2. Implanted DJBL. 
Previously studies with obese patients that used the duodenojejunal bypass liner (DJBL) 
demonstrated a significant weight loss. In addition, an improvement in the control of T2DM 
was observed, which was statistically greater than that of the group treated with a low-
calorie diet [26-33].  
Our group in the Gastrointestinal Endoscopy Unit of the University of São Paulo School of 
Medicine performed a prospective study to evaluates the effectiveness of this method over 
the control of hyperlipidemia, improvement of insulin resistance, metabolic syndrome, and 
in the potential benefit in the reduction of cardiovascular risk [34]. 
The inclusion criteria of the study were ages between 18 and 65 years, BMI≥35 kg/m2, T2DM 
with or without other comorbidities, and a triglyceride/high-density lipoprotein cholesterol 
ratio (TG/HDL) ratio greater than or equal to 3.5, indicating insulin resistance. 
To identify patients with resistance to insulin and metabolic syndrome, TG/HDL ratio has 
proved to be an excellent practical indicator. This ratio estimates the resistance to insulin and is 
as accurate in terms of the clinical criteria for metabolic syndrome as specified by the Adult 
Treatment Panel III [6], the measure of the fasting concentration of plasma insulin,or other 
estimates that measure glycemia and the plasma concentration of insulin in order to identify 
individuals with insulin resistance [5, 7,8]. In addition, the TG/HDL ratio has proved to be an 
independent factor that was correlated with the risk of cardiovascular events [5]. 
A low TG/HDL ratio indicates large particles and a lower atherogenic potential of LDL 
cholesterol, while a high TG/ HDL ratio indicates a large population of small, dense, and 
pro-atherogenic particles of LDL cholesterol [7]. The lipid disorder consisting of the increase 
of plasma triglycerides and the reduction of HDL cholesterol, known as atherogenic 
dyslipidemia, is directly associated with insulin resistance  and is also an independent risk 
factor for cardiovascular diseases [3–5, 7]. 
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Eighty-one patients were selected for implantation of the device. Of these, 78 successfully 
received the implant and three were not given the implant due to anatomic factors (short 
bulb). Among the 78 patients, one was excluded from the analysis for not having performed 
the laboratory measures. Of the 77 remaining patients, we calculated the initial TG/ HDL 
ratio (at the time of the implant), identifying 54 patients (70%) with a ratio greater than or 
equal to 3.5, indicating the presence of insulin resistance and metabolic syndrome. These 
patients were included in the study and were monitored in order to evaluate whether or not 
an improvement occurred in this ratio during the period in which they had the implanted 
device. 
We compared the TG/HDL ratio at the time of the implant with the ratio obtained after 6 
months to evaluate whether there was an improvement in insulin resistance. We divided the 
patients into two groups: those who demonstrated a ratio below 3.5 in the end of the study, 
considered as control of the insulin resistance, and those that did not demonstrate values 
lower than 3.5. In the two groups, we evaluated whether control of T2DM and weight loss 
occurred during this period, and we correlated the influence of the control of diabetes and 
weight loss with the improvement of TG/HDL. We considered a significant weight loss to be 
a reduction of at least 10% of initial body weight and control of T2DM as an HbA1c level 
lower than 7%. The patients who presented a reduction of HbA1c levels greater than 1.5% 
yet did not obtain values lower than 7% were considered to have partial control over DM2. 
The overall initial average of the TG/HDL ratio was 5.75 and presented a significant 
reduction down to 4.36 at the end of the 6 months (p=<0.001), indicating an improvement of 
insulin resistance (Table 1). Of these patients, 23 (42.6%) presented control of the TG/HDL 
ratio with values lower than 3.5 at the end of the study. This group presented a significant 
improvement in the ratio, which decreased from 5.15 to 2.85 (p<0.001). Thirty-one patients 
did not show a controlled TG/HDL ratio but rather a discrete improvement, with an initial 











54 5,75 4,36 0,001 
Controlled TG/HDL 
at the end 
23 5,15 2,85 <0,001 
Not controlled 
TG/HDL at the end
31 6,2 5,47 0,1641 
Table 1. Improvement on TG/HDL ratio. 
In order to identify the differences between the group that presented an improvement in the 
ratio and the group that did not, we evaluated the control of T2DM (HbA1c improvement) 
and the success of weight loss (reduction >10% of initial weight). 
In the evaluation of T2DM control (Table 2), we observed that all patients presented a 
significant improvement in the levels of HbA1c (p<0.001). In the group that controlled the 
 
Lipoproteins – Role in Health and Diseases 296 
TG/HDL ratio, three patients already had diabetes controlled at the beginning of the study, 
with an initial average of HbA1c of 6.4% and a final of 5.83% (p=0.023). Fifteen patients did not 
have diabetes under control, presenting an initial average of 7.8%, and then developing control 
of T2DM, with a final average of 6.1% (p<0.001). Five patients did not have diabetes 
undercontrol and obtained partial control after the intervention. These patients presented 
higher initial levels of HbA1c than those of the group that controlled diabetes, with an initial 
average of 10.34%, and presented a significant reduction of the final average of 8.88% (p=0.03). 
In the group that did not control the TG/HDL ratio, five patients already had T2DM under 
control, with an initial average of 6.6%mg/dl and a final average of 6.2% (p=0.037). Fifteen 
patients did not have diabetes under control and were able to bring it under control with 
initial and final averages of 8.5% and 6.4%, respectively (p=0.001). Eleven patients did not 
have diabetes under control and obtained partial control. These patients also presented a 
higher level of HbA1c than that of the patients who had controlled T2DM, with an initial 
average of 9.9%, reaching a significant reduction at the end of the study with an average of 
7.7% (p=0.003), which is very close to the level required for T2DM control.  
An association was not observed between the control of T2DM and an improvement in the 
TG/HDL ratio (Table 3). 
 
Diabetes improvement on TG/HDL controlled patients








3 6,4 5,38 0,023 
Not controled who 
controlled 
15 7,8 6,1 <0,001 
Not controlled with 
partial control 
11 10,34 8,88 0,03 
HbA1c Worsening 0 - - . 









5 6,6 6,2 0,037 
Not controled who 
controlled 
15 8,5 6,4 0,001 
Not controlled with 
partial control 
11 9,9 7,7 0,003 
HbA1c Worsening 0 - - . 
Legend: Diabetes evolution on TG/HDL controlled and not controlled patients. Glycemic improvement was 
statistically significant in all groups of patients. 
Table 2. Diabetes improvement. 
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(n = 23) 




5 15 11 0 
Legend: Relationship between improvement of diabetes and TG/HDL control. Patients improved diabetes regardless 
of having controlled the TG/HDL ratio (p 0,35). 
Table 3. Relation between TG/HDL ratio control and HbA1C control. 
In relation to weight loss (Table 4), the patients lost on average 12.6% of their initial weight. 
Among the 23 patients who controlled their TG/HDL ratio, 19 (82.6%) lost more than 10% of 
their initial weight. The average initial weight of these patients was 116.5 kg and the average 
final weight was 97 kg, constituting an average loss of 16.7% of initial weight. Four patients 
did not lose more than 10% of their weight. The average initial weight of these patients was 
94.4 kg, and the average final weight was 87.47 kg, marking an average loss of 7.4%. In the 
group that did not control the TG/HDL ratio, 15 lost more than 10% of their initial weight 
(48%), with an average initial weight of 123.9 kg and an average final weight of 105.7 kg 
(loss of 14.6% in initial weight). Sixteen patients did not lose more than 10% of their weight, 
presenting an average initial weight of 111.9 kg and an average final weight of 103.5 kg, 
with an average loss of 7.5% in initial weight. 
 





weight - Kg 
Final average 
weight - Kg 
Percentage of 
loss 
Over than 10% of 
initial weight 
19 (82,6) 116,5 97 16,7 
Less than 10% of 
initial weight 
4 (17,4) 94,4 87,47 7,4 










Over than 10% of 
initial weight 
15 (48) 123,9 105,7 14,6 
Less than 10% of 
initial weight 
16 (52) 111,9 103,5 7,5 
Table 4. Weight loss 
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Comparing the patients who lost weight with the patients who controlled their TG/HDL 
ratio, an association can be observed between a weight loss greater than 10% of initial 




Over than 10% of 
inicial weight 




N (average  
weight loss %) 
19 (16,7) 4 (7,4) 23 
TG/HDL not controlled
N (average  
weight loss %) 
15 (14,6) 16 (7,5) 31 
Legend: Relationship between weight loss and TG/HDL control. Control of TG/HDL ratio is related to weight loss 
greater than 10% of initial weight. (p 0,01-  OR 5,06). 
Table 5. Relation between TG/HDL ratio control and weight loss. 
Of the 54 patients included in this 6 months study, 38 have completed  (26 completed 24 
weeks, 12 completed 20 weeks). Among the 16 patients left, 12 had the device removed at 
16 weeks, 2 at 12 weeks, and 2 had the implant for just 4 weeks. The early implant 
removals occurred due to migration of the device in nine patients, the observation of a 
free device anchor during endoscopic exam in four patients, the presence of bleeding 
without migration in one patient, subject request in one case, and due to the decision of 
the researcher in one case. 
In resume, all patients implanted with the device presented a statistically significant 
reduction of the levels of HbA1c, and the majority of these patients (70.3%) presented 
values lower than 7% at the end of the study and were therefore considered to be 
controlled diabetics. In addition, all patients presented a statistically significant reduction 
of initial weight, with an average general loss of 12.6% of initial weight. Regarding the 
improvement of insulin resistance and metabolic syndrome, there was a significant 
reduction of the TG/HDL ratio from 5.75 to 4.36 (p=0.0001). Of these patients, 42.6% 
controlled their insulin resistance, presenting a TG/HDL ratio value lower than 3.5 at the 
end of the study. 
Among the patients who controlled the TG/HDL ratio, the reduction of the ratio went from 
6.8 at the beginning of the study to 2.8 at the end (p<0.001). 
In other study conducted by our group,  twenty two implanted patients were followed 
during a period of 1 year [13]. In the full analysis population, the mean percentage excess 
weight loss was 35.5% (P < 0.0001). The reduction in excess body weight was reflected by 
reductions in BMI and waist circumference of  6.7  kg/m2 and  13.0 cm, respectively. 
The improvement in glycemic control is convincingly demonstrated by the results with a 
percentage of subjects with HbA1c < 7% at baseline improved from 4.5% to 73.0% at final 
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study assessment. Statistically significant reductions in fasting blood glucose ( - 30.3 ± 10.2 
mg/dL), fasting insulin ( - 7.3 ± 2.6 lU/mL), and HbA1c ( - 2.1 ± 0.3%) were observed. 
Blood levels of total cholesterol, low-density lipoprotein cholesterol, and triglycerides also  
were significantly reduced during the study. 
On this one year series, thirteen subjects completed the 52-week period, and 18 subjects 
completed at least 24 weeks. The mean duration of the implant period for all subjects was 41.9 
± 3.2 weeks. The reasons for early removal of the device were migration or rotation of the 
device (n = 3; 36, 36, and 48 weeks post implantation), GI bleeding (n = 1; 4 weeks post 
implantation), abdominal pain (n = 2; 21 and 30 weeks post-implantation), and principal 
investigator request due to subject’s non compliance with study visits (n = 2; 20 and 32 weeks 
post implantation). The device was removed from one subject who presented an  abdominal 
tumor  not related to the device. 
Sixteen subjects had HbA1c measured 3 and/or 6 months after explantation of the DJBL. 
These subjects demonstrated a mean decrease in HbA1c during the original 52-week study 
of - 2.3 ± 0.4%. Three and 6 months after removal of the device, their mean changes from 
baseline were - 2.3 ± 0.3% (n = 15) and - 1.7 – 0.7% (n = 11), respectively. 
The DJBL offers a new non-surgical therapeutic possibility, positioned between 
pharmacological drugs and the various techniques employed in bariatric surgery. This 
technology platform may be employed prior to bariatric surgery to help control T2DM, in 
order to promote weight loss and a reduction of visceral fat, lipid control, a reduction of 
insulin resistance, and of cardiovascular risk,minimizing the risk of per operative clinical 
complications, accustoming the patient to a restricted diet that will be necessary in the post-
operative period and can even be used as a substitution for bariatric surgery as a less 
invasive technique in selected cases. 
5. Conclusion 
As the prevalence of obesity increases, less invasive methods will be needed to obtain a 
sustained weight loss. Some new endoscopic tools and methods are being investigated and 
they could be applied as first-line therapy for obesity, to control the metabolic comorbidities, 
to reduce the operatory risk prior bariatric and metabolic surgery and as substitution of 
surgery in selected cases. 
The intragastric baloon and the Duodeno Jejunal Bypass Liner are tools with promising 
results in the endoscopic treatment of obesity. They are still subject of  research with a great 
potential for improvement. Although outcomes from the use of the intragastric baloon and 
the DJBL are not comparable to those of surgery with regard to weight loss and late results, 
these new techniques have showed an excelent result in ameliorating health status, in the 
control of  the metabolic syndrome as well as improving the quality of life for a  well 
selected group of patients. 
 
Lipoproteins – Role in Health and Diseases 300 
Author details 
Eduardo Guimarães Hourneaux de Moura*,  
Bruno da Costa Martins, Guilherme Sauniti Lopes 
Department of Gastroenterology, Gastrointestinal Endoscopy Unit,  
Hospital das Clínicas - University of São Paulo School of Medicine, São Paulo, Brazil 
Ivan Roberto Bonotto Orso 
Department of Gastroenterology, Gastrointestinal Endoscopy Unit,  
Hospital das Clínicas - University of São Paulo School of Medicine. São Paulo, Brazil 
Department of Surgery, School of Medicine of the Assis Gurgacz Faculty,  
Gastroclínica Cascavel, Brazil 
6. References 
[1] Bogers RP, Bemelmans WJ, Hoogenveen RT, et al. Association of overweight with 
increased risk of coronary heart disease partly independent of blood pressure and 
cholesterol levels: a metaanalysis of 21 cohort studies including more than 300 000 
persons. Arch Intern Med. 2007;167(16):1720–8. 
[2] Kumar N, Thompson CC. Endoscopic solutions for weight loss. Current Opinion in 
Gastroenterology 2011, 27:407–41 
[3] McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight 
individuals who are insulin resistant. Ann Intern Med. 2003;139:802–9.  
[4] Shishehbor MH, Hoogwef BJ, Lauer MS. Association of triglyceride to HDL cholesterol 
ratio with heart rate recovery. Diabetes Care. 2004;27(4):936–41.  
[5] McLaughlin T, Reaven G, Abbasi F, et al. Is there a simple way to identify insulin 
resistant individuals at increased risk of cardiovascular disease? Am J Cardiol. 
2005;96(3):399–404.  
[6] Tong PC, Kong AP, SoWY, et al. The usefulness of the international diabetes federation 
and the national cholesterol education program’s Adult Treatment Panel III definitions 
of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 
diabetes. Diabetes Care. 2007;30(5):1206–11.  
[7] Hadaegh F, Dhalili D, Ghasemi A, et al. Triglyceride/HDLcholesterol ratio is an 
independent predictor for coronary heart disease in a population of Iranian men. Nutr 
Metab CardiovascDis. 2009;19(6):401–8.  
[8] Vasques ACJ, Rosado LEFPM, Rosado GP, et al. Indicadores do perfil lipídico plasmático 
relacionados à resistência á insulina. Rev Assoc Méd Bras. 2009;55(3):342–6.  
[9] Quizada Z, Paoli M, Zerpa Y, et al. The triglyceride/HDL cholesterol ratio as a marker of 
cardiovascular risk in obesechildren; association with traditional and emergent risk 
factors. Pediatr Diabetes. 2008;9(5):464–71.  
[10] Kannel WB, Vasan RS, Keyes MJ, et al. Usefulness of the triglyceride high density 
lipoprotein versus the cholesterol high density lipoprotein ratio for predicting insulin 
                                                                 
*Corresponding Author 
 
Endoscopic Treatment of Metabolic Syndrome 301 
resistance and cardiometabolic risk (from the Framingham Offspring Cohort). Am J 
Cardiol. 2008;101(4):497–501.  
[11] Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and 
overweight: update and meta-analysis. Br Med J 2007;335: 1194-9.) 
[12] Lee WJ,  Lee YC, Ser KH, Chen JC,  Chen SC. Improvement of Insulin Resistance After 
Obesity Surgery: A Comparison of Gastric Banding and Bypass Procedures Obes Surg  
2008; 18:1119–1125 
[13] Moura,EGH,  Martins BC, Lopes GS,  Orso IR, Oliveira SL, Galva˜o Neto MP, et al. 
Metabolic Improvements in Obese Type 2 Diabetes Subjects Implanted for 1 Year with 
an Endoscopically Deployed Duodenal–Jejunal Bypass Liner. Diabetes Technol Ther 
2012;14(2). DOI: 10.1089/dia.2011.0152 
[14] Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G et al, The Mechanism 
of Diabetes Control After Gastrointestinal Bypass Surgery Reveals a Role of the Proximal 
Small Intestine in the Pathophysiology of Type 2. Ann Surg 2006;244: 741–749 
[15] Mason EE. The mechanism of surgical treatment of type 2 diabetes. Obes Surg. 
2005;15:459–461. 
[16] Patriti A, Facchiano E, Sanna A, et al. The enteroinsular axis and the recovery from type 
2 diabetes after bariatric surgery. Obes Surg. 2004; 14:840–848. 
[17] Pories WJ, Albrecht RJ. Etiology of type II diabetes mellitus: role of the foregut. World J 
Surg. 2001;25:527–531. 
[18] Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric 
bypass on hormones involved in body weight regulation and glucose metabolism. Ann 
Surg. 2004;240:236 –242. 
[19] Kelly DE, Wing R, Buonocore C, et al. Relative effect soft calorie restriction and weight loss 
in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1993;77:1287–93. 21.  
[20] Ash S, Reeves MM, Yeo S, et al. Effect of intensive dietetic interventions on weight and 
glycemic control in overweight men with type II diabetes: a randomized trial. Int J 
Obes. 2003;27: 797–802.) 
[21] Imaz I, Martı´nez-Cervell C, Garcı´a-Alvarez EE, et al. Safety and effectiveness of the 
intragastric balloon for obesity. A meta-analysis. Obes Surg 2008;7:841–846. 
[22] Dumonceau JM. Evidence-based Review of the Bioenterics Intragastric Balloon for 
Weight Loss. Obes Surg (2008) 18:1611–1617 
[23] Forlano R, Ippolito AM, Iacobellis A, et al. Effect of the BioEnterics intragastric balloon 
on weight, insulin resistance, and liver steatosis in obese patients. Gastrointest Endosc 
2010; 71:927–933. 
[24] Herve J, Wahlen CH, Schaeken A, et al. What becomes of patients one year after the 
intragastric balloon has been removed? Obes Surg. 2005;15:864–70.  
[25] Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment- resistant obesity: 
safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-
free follow-up. Gastrointest Endosc. 2005;61:19–27. 
[26] Gersin KS, Keller JE, Stefanidis D, et al. Duodenal–jejunal bypass sleeve: a totally 
endoscopic device for the treatment of morbid obesity. Surg Innov. 2007;14(4):275–8. 
[27]  Schauer P, Chand B, Brethauer S. New applications for endoscopy: the emerging field 
of endoluminal and transgastric bariatric surgery. Surg Endosc. 2007;21:347–56. 
 
Lipoproteins – Role in Health and Diseases 302 
[28] Tarnoff M, Shikora S, Lembo A, et al. Chronic in-vivo experience with an 
endoscopically delivered and retrieved duodenal–jejunal bypass sleeve in a porcine 
model. SurG Endosc. 2008;22(4):1023–8. 
[29] Tarnoff M, Shikora S, Lembo A. Acute technical feasibility of an endoscopic duodenal–
jejunal bypass sleeve in a porcine model: a potentially novel treatment for obesity and 
type 2 diabetes. Surg Endosc. 2008;22(3):772–6. 
[30] Tarnoff M, Rodriguez L, Escalona A, et al. Open label, prospective, randomized 
controlled trial of an endoscopic duodenal–jejunal bypass sleeve versus low calorie diet 
for pre-operative weight loss in bariatric surgery. Surg Endosc. 2009;23(3):650–6. 
[31] Rodriguez-Grunert L, Galvao Neto MP, Alamo M, et al. First human experience with 
endoscopically delivered and retrieved duodenal– jejunal bypass sleeve. Surg Obes 
Relat Dis. 2008;4(1):55–9. 
[32] Rodriguez L, Reyes E, Fagalde P, et al. Pilot clinical study of an endoscopic, removable 
duodenal–jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol 
Ther. 2009;11 (11):725–32.  
[33] Schouten R, Rijs CS, Bouvy ND, et al. A multicenter, randomized efficacy study of the 
EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. 
Ann Surg. 2010;251(2):236–43 
[34] Moura EGH, Orso IR, Martins BC, Lopes GS, Oliveira SL, et al. Improvement of Insulin 
Resistance and Reduction of Cardiovascular Risk Among Obese Patients with Type 2 
Diabetes with the Duodenojejunal Bypass Liner. Obes Surg (2011) 21:941–947 
